Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Coronavirus Update: After Green Light In Canada, US Awaits Pfizer/BioNTech Vaccine Authorization

Plus: Changes At UK Taskforce

Executive Summary

Pfizer and BioNTech's COVID-19 vaccine picks up its third emergency authorization, with all eyes now on the final decision from the US FDA. Elsewhere, there are changes at the UK's vaccine taskforce, while Korea is moving ahead with vaccine development plans.  

You may also be interested in...

Pfizer Allergy Warning Is First Test Of UK Vaccine Roll-Out

Individuals with history of significant allergic reactions are now being told not to have the vaccine after warnings were not included in healthcare professional information.

UK Grants First Worldwide Authorization For Pfizer/BioNTech COVID-19 Vaccine

The UK's MHRA has granted an emergency authorization to the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.

UK Vaccine Taskforce Leader Under Scrutiny After Investor Meeting

The UK has built one of the biggest and best ‘portfolios’ of COVID-19 vaccine candidates – but there are questions about its transparency and accountability.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts